Tejeshwar Jain
Overview
Explore the profile of Tejeshwar Jain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bava E, Jain T, Al-Obaidi M, Evans Z, Doto D, Vege S, et al.
Pancreatology
. 2025 Jan;
PMID: 39864969
Background: Acute Pancreatitis (AP) is a formidable disease with significant morbidity, mortality and healthcare expenditure. There is an emergent need to develop therapeutic agents for this disease as there are...
2.
Iyer S, Tarique M, Sahay P, Giri S, Bava E, Guan J, et al.
Am J Physiol Gastrointest Liver Physiol
. 2024 Nov;
328(4):G342-G363.
PMID: 39499252
Chronic pancreatitis (CP) is a fibro-inflammatory disease of the pancreas with no specific cure. Research highlighting the pathogenesis and especially the therapeutic aspect remains limited. Aberrant activation of developmental pathways...
3.
Sickels A, Jain T, Dudeja V
Ann Surg Oncol
. 2023 Jul;
30(11):6308-6310.
PMID: 37482596
No abstract available.
4.
Jain T, Dudeja V
Cancer Discov
. 2022 Aug;
12(8):1838-1840.
PMID: 35929130
In this issue of Cancer Discovery, Drewes and colleagues demonstrate a surprising role for the common gut pathogen Clostridioides difficile in driving colorectal cancer in preclinical models through the bacterial...
5.
Jain T, Sharma P, Giri B, Iyer S, Sethi V, Bava E, et al.
HPB (Oxford)
. 2022 Jun;
24(10):1729-1737.
PMID: 35717430
Background: Exocrine pancreatic insufficiency (EPI) is frequently seen in patients with pancreatic cancer (PDAC) and is thought to contribute to nutritional complications. While EPI can be pharmacologically temporized with pancreatic...
6.
Palathingal Bava E, George J, Iyer S, Sahay P, Tarique M, Jain T, et al.
Pancreatology
. 2022 May;
22(5):553-563.
PMID: 35570091
Chronic pancreatitis (CP) is an irreversible fibro-inflammatory disease of the pancreas with no current targeted therapy. Pirfenidone, an anti-fibrotic and anti-inflammatory drug, is FDA approved for treatment of Idiopathic Pulmonary...
7.
Vaish U, Jain T, Are A, Dudeja V
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948209
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity and mortality in the western world, with limited therapeutic strategies and dismal long-term survival. Cancer-associated fibroblasts (CAFs) are key...
8.
Palathingal Bava E, George J, Tarique M, Iyer S, Sahay P, Gomez Aguilar B, et al.
JCI Insight
. 2021 Nov;
7(2).
PMID: 34847076
Despite decades of research, there is no specific therapy for acute pancreatitis (AP). In the current study, we have evaluated the efficacy of pirfenidone, an antiinflammatory and antifibrotic agent that...
9.
Giri B, Sharma P, Jain T, Ferrantella A, Vaish U, Mehra S, et al.
Oncoimmunology
. 2021 Sep;
10(1):1976952.
PMID: 34552825
Heat shock protein 70 (Hsp70), a protein chaperone, is known to promote cell survival and tumor progression. However, its role in the tumor microenvironment (TME) is largely unknown. We specifically...
10.
Jain T, Sharma P, Are A, Vickers S, Dudeja V
Front Immunol
. 2021 Mar;
12:622064.
PMID: 33708214
The past decade has witnessed groundbreaking advances in the field of microbiome research. An area where immense implications of the microbiome have been demonstrated is tumor biology. The microbiome affects...